Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Management of Facial Contact Dermatitis in Adults

Introduction to Treatment

  • The American Academy of Dermatology recommends low-potency topical corticosteroids, such as hydrocortisone 1% or hydrocortisone butyrate 0.1%, as first-line treatment for contact dermatitis on the face in adults due to the sensitive nature of facial skin and risk of steroid-induced side effects with higher potency options 1, 2

Steroid Selection

  • For mild to moderate cases, low potency (Class 6-7) steroids such as hydrocortisone 1% or 2.5% cream are recommended 3, 2
  • Hydrocortisone butyrate 0.1% cream is also a suitable option for mild to moderate cases 4, 1
  • Desonide 0.05% cream and fluocinolone acetonide 0.01% cream are additional low-potency steroid options 1, 3

Application and Dosage

  • Apply a thin layer of topical steroid to affected areas once or twice daily 1
  • Use the fingertip unit method for appropriate dosing, with 2 fingertip units recommended for the face 2
  • Apply moisturizer after steroid application to enhance barrier function 5, 2

Special Considerations

  • Facial skin is thinner and more prone to steroid-induced atrophy, telangiectasia, and hypopigmentation, so high-potency steroids should be avoided 1
  • Consider topical calcineurin inhibitors, such as tacrolimus or pimecrolimus, for severe or resistant cases, or if concerned about steroid side effects 5, 6
  • For eyelids or periorbital areas, use only hydrocortisone 1% or consider tacrolimus/pimecrolimus due to risk of glaucoma and cataracts with steroids 1

Follow-up and Maintenance

  • If no improvement after 7 days of appropriate therapy, reassess diagnosis, and for recurrent cases, consider maintenance therapy with non-steroid alternatives like moisturizers or topical calcineurin inhibitors 5, 1
  • For chronic cases requiring longer treatment, use a "weekend therapy" approach (twice weekly application) to minimize side effects 1, 4